Planned divestment of Celgene’s psoriasis blockbuster means instant cashback for Bristol, a result the markets see as a win-win-win.
GE sells its Biopharma business for $21.4bn, but is its IPO cancelled or merely on hold?
Bain Capital’s investment in a clutch of Pfizer neurology projects raises the question of what interest private equity might have in financing risky biopharma research…
The UK company Midatech Pharma is giving up on speciality drugs to focus on cancer and rare diseases – and it has Novartis in its sights.
Higher-risk novel drug development is chosen over lower-cost volume play as US biosimilar growth continues to sputter.
The Spanish group shows again that there is a future in dermatology, but its Allergan deal really depends on the fate of one asset.
GE arrives to the spin-out party fashionably late.
J&J sells another unit.